Skip to main content
PMC home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2003 Dec;111(16):1851–1854. doi: 10.1289/ehp.6511

Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed.

Frederick J de Serres 1
PMCID: PMC1241756  PMID: 14654440

Abstract

Articles in the literature on alpha-1 antitrypsin (AAT) deficiency have been interpreted as indicating that AAT deficiency is a rare disease that affects mainly Caucasians (whites) from northern Europe. In a recent publication on the worldwide racial and ethnic distribution of AAT deficiency, new data were presented demonstrating that it is also found in various populations of African blacks; Arabs and Jews in the Middle East; and Central, Far East, and Southeast Asians, as well as whites in Australia, Europe, New Zealand, and North America. The new data on the prevalence of AAT deficiency in other major racial groups worldwide will affect the standards for the diagnosis of AAT deficiency by the medical community, with the realization that is not a rare disease of whites in northern Europe and immigrants from these countries in the New World. In a total population of 4.4 billion in the 58 countries surveyed, there are at least 116 million carriers (those with Pi phenotypes PiMS and PiMZ) and 3.4 million with deficiency allele combinations (phenotypes PiSS, PiSZ, and PiZZ) for the two most prevalent deficiency alleles PiS and PiZ; therefore, the new data suggest that AAT deficiency may be one of the most common serious single-locus genetic diseases in the world. Particularly important is the unique susceptibility of AAT-deficient individuals to exposure to chemical and particulate environmental agents. Such exposures are known to result in both lung and liver disease as well as other adverse health effects.

Full Text

The Full Text of this article is available as a PDF (116.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bazex Jacques, Bayle Paule, Albes Brigitte. Le déficit en alpha-1-antitrypsine. Place au sein des états pathologiques cutanés. Bull Acad Natl Med. 2002;186(8):1479–1487. [PubMed] [Google Scholar]
  2. Blanco I., Fernández E., Bustillo E. F. Alpha-1-antitrypsin PI phenotypes S and Z in Europe: an analysis of the published surveys. Clin Genet. 2001 Jul;60(1):31–41. doi: 10.1034/j.1399-0004.2001.600105.x. [DOI] [PubMed] [Google Scholar]
  3. Blank C. A., Brantly M. Clinical features and molecular characteristics of alpha 1-antitrypsin deficiency. Ann Allergy. 1994 Feb;72(2):105–122. [PubMed] [Google Scholar]
  4. Brantly M. L., Paul L. D., Miller B. H., Falk R. T., Wu M., Crystal R. G. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis. 1988 Aug;138(2):327–336. doi: 10.1164/ajrccm/138.2.327. [DOI] [PubMed] [Google Scholar]
  5. Buist A. S., Burrows B., Eriksson S., Mittman C., Wu M. The natural history of air-flow obstruction in PiZ emphysema. Report of an NHLBI workshop. Am Rev Respir Dis. 1983 Feb;127(2):S43–S45. doi: 10.1164/arrd.1983.127.2P2.S43. [DOI] [PubMed] [Google Scholar]
  6. Byth B. C., Billingsley G. D., Cox D. W. Physical and genetic mapping of the serpin gene cluster at 14q32.1: allelic association and a unique haplotype associated with alpha 1-antitrypsin deficiency. Am J Hum Genet. 1994 Jul;55(1):126–133. [PMC free article] [PubMed] [Google Scholar]
  7. Carlson J., Eriksson S. Chronic 'cryptogenic' liver disease and malignant hepatoma in intermediate alpha 1-antitrypsin deficiency identified by a Pi Z-specific monoclonal antibody. Scand J Gastroenterol. 1985 Sep;20(7):835–842. doi: 10.3109/00365528509088831. [DOI] [PubMed] [Google Scholar]
  8. Carrell Robin W., Lomas David A. Alpha1-antitrypsin deficiency--a model for conformational diseases. N Engl J Med. 2002 Jan 3;346(1):45–53. doi: 10.1056/NEJMra010772. [DOI] [PubMed] [Google Scholar]
  9. Colp C., Pappas J., Moran D., Lieberman J. Variants of alpha 1-antitrypsin in Puerto Rican children with asthma. Chest. 1993 Mar;103(3):812–815. doi: 10.1378/chest.103.3.812. [DOI] [PubMed] [Google Scholar]
  10. Cox D. W., Billingsley G. D., Mansfield T. DNA restriction-site polymorphisms associated with the alpha 1-antitrypsin gene. Am J Hum Genet. 1987 Nov;41(5):891–906. [PMC free article] [PubMed] [Google Scholar]
  11. Cox D. W., Woo S. L., Mansfield T. DNA restriction fragments associated with alpha 1-antitrypsin indicate a single origin for deficiency allele PI Z. Nature. 1985 Jul 4;316(6023):79–81. doi: 10.1038/316079a0. [DOI] [PubMed] [Google Scholar]
  12. Crystal R. G., Brantly M. L., Hubbard R. C., Curiel D. T., States D. J., Holmes M. D. The alpha 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. Chest. 1989 Jan;95(1):196–208. doi: 10.1378/chest.95.1.196. [DOI] [PubMed] [Google Scholar]
  13. Dirksen A., Dijkman J. H., Madsen F., Stoel B., Hutchison D. C., Ulrik C. S., Skovgaard L. T., Kok-Jensen A., Rudolphus A., Seersholm N. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1468–1472. doi: 10.1164/ajrccm.160.5.9901055. [DOI] [PubMed] [Google Scholar]
  14. Endres W. Inherited metabolic diseases affecting the carrier. J Inherit Metab Dis. 1997 Mar;20(1):9–20. doi: 10.1023/a:1005397120726. [DOI] [PubMed] [Google Scholar]
  15. Fagerhol M. K., Cox D. W. The Pi polymorphism: genetic, biochemical, and clinical aspects of human alpha 1-antitrypsin. Adv Hum Genet. 1981;11:1-62, 371-2. [PubMed] [Google Scholar]
  16. Feld R. D. Heterozygosity of alpha 1-antitrypsin: a health risk? Crit Rev Clin Lab Sci. 1989;27(6):461–481. doi: 10.3109/10408368909114595. [DOI] [PubMed] [Google Scholar]
  17. Fischer Stefan, Strüber Martin, Haverich Axel. Aktuelles bei der Lungentransplantation. Patienten, Indikationen, Techniken und Ergebnisse. Med Klin (Munich) 2002 Mar 15;97(3):137–143. doi: 10.1007/s00063-002-1137-9. [DOI] [PubMed] [Google Scholar]
  18. Gourley M. F., Gourley G. R., Gilbert E. F., Odell G. B. Alpha 1-antitrypsin deficiency and the PiMS phenotype: case report and literature review. J Pediatr Gastroenterol Nutr. 1989 Jan;8(1):116–121. doi: 10.1097/00005176-198901000-00021. [DOI] [PubMed] [Google Scholar]
  19. Graziadei I. W., Joseph J. J., Wiesner R. H., Therneau T. M., Batts K. P., Porayko M. K. Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency. Hepatology. 1998 Oct;28(4):1058–1063. doi: 10.1002/hep.510280421. [DOI] [PubMed] [Google Scholar]
  20. Hutchison D. C. S., Cooper D., British Thoracic Society Alpha-1-antitrypsin deficiency: smoking, decline in lung function and implications for therapeutic trials. Respir Med. 2002 Nov;96(11):872–880. doi: 10.1053/rmed.2002.1381. [DOI] [PubMed] [Google Scholar]
  21. Hutchison D. C. Alpha 1-antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. Respir Med. 1998 Mar;92(3):367–377. doi: 10.1016/s0954-6111(98)90278-5. [DOI] [PubMed] [Google Scholar]
  22. Hutchison D. C. Natural history of alpha-1-protease inhibitor deficiency. Am J Med. 1988 Jun 24;84(6A):3–12. doi: 10.1016/0002-9343(88)90153-2. [DOI] [PubMed] [Google Scholar]
  23. Janus E. D., Phillips N. T., Carrell R. W. Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet. 1985 Jan 19;1(8421):152–154. doi: 10.1016/s0140-6736(85)91916-6. [DOI] [PubMed] [Google Scholar]
  24. Kayler Liise K., Merion Robert M., Lee Samuel, Sung Randall S., Punch Jeffrey D., Rudich Steven M., Turcotte Jeremiah G., Campbell Darrell A., Jr, Holmes Ronald, Magee John C. Long-term survival after liver transplantation in children with metabolic disorders. Pediatr Transplant. 2002 Aug;6(4):295–300. doi: 10.1034/j.1399-3046.2002.02009.x. [DOI] [PubMed] [Google Scholar]
  25. Kelada Samir N., Eaton David L., Wang Sophia S., Rothman Nathaniel R., Khoury Muin J. The role of genetic polymorphisms in environmental health. Environ Health Perspect. 2003 Jun;111(8):1055–1064. doi: 10.1289/ehp.6065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lieberman J., Silton R. M., Agliozzo C. M., McMahon J. Hepatocellular carcinoma and intermediate alpha1-antitrypsin deficiency (MZ phenotype). Am J Clin Pathol. 1975 Sep;64(3):304–310. doi: 10.1093/ajcp/64.3.304. [DOI] [PubMed] [Google Scholar]
  27. Lieberman J., Winter B., Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986 Mar;89(3):370–373. doi: 10.1378/chest.89.3.370. [DOI] [PubMed] [Google Scholar]
  28. Lima L. C., Matte U., Leistner S., Bopp A. R., Scholl V. C., Giugliani R., da Silveira T. R. Molecular analysis of the Pi*Z allele in patients with liver disease. Am J Med Genet. 2001 Dec 15;104(4):287–290. doi: 10.1002/ajmg.10069. [DOI] [PubMed] [Google Scholar]
  29. Lolin Y. I., Ward A. M. Alpha-1-antitrypsin phenotypes and associated disease patterns in neurological patients. Acta Neurol Scand. 1995 May;91(5):394–398. doi: 10.1111/j.1600-0404.1995.tb07027.x. [DOI] [PubMed] [Google Scholar]
  30. Lomas D. A., Evans D. L., Finch J. T., Carrell R. W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992 Jun 18;357(6379):605–607. doi: 10.1038/357605a0. [DOI] [PubMed] [Google Scholar]
  31. Lomas D. A. Loop-sheet polymerization: the mechanism of alpha1-antitrypsin deficiency. Respir Med. 2000 Aug;94 (Suppl 100):S3–S6. doi: 10.1053/rmed.2000.0850. [DOI] [PubMed] [Google Scholar]
  32. Mahadeva R., Lomas D. A. Genetics and respiratory disease. 2. Alpha 1-antitrypsin deficiency, cirrhosis and emphysema. Thorax. 1998 Jun;53(6):501–505. doi: 10.1136/thx.53.6.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Marcus N., Teckman J. H., Perlmutter D. H. Alpha1-antitrypsin deficiency: from genotype to childhood disease. J Pediatr Gastroenterol Nutr. 1998 Jul;27(1):65–74. doi: 10.1097/00005176-199807000-00012. [DOI] [PubMed] [Google Scholar]
  34. Mayer A. S., Stoller J. K., Bucher Bartelson B., James Ruttenber A., Sandhaus R. A., Newman L. S. Occupational exposure risks in individuals with PI*Z alpha(1)-antitrypsin deficiency. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):553–558. doi: 10.1164/ajrccm.162.2.9907117. [DOI] [PubMed] [Google Scholar]
  35. O'Riordan K., Blei A., Rao M. S., Abecassis M. alpha 1-antitrypsin deficiency-associated panniculitis: resolution with intravenous alpha 1-antitrypsin administration and liver transplantation. Transplantation. 1997 Feb 15;63(3):480–482. doi: 10.1097/00007890-199702150-00028. [DOI] [PubMed] [Google Scholar]
  36. Parmar Jasvir S., Mahadeva Ravi, Reed Benjamin J., Farahi Neda, Cadwallader Karen A., Keogan Mary T., Bilton Diana, Chilvers Edwin R., Lomas David A. Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol. 2002 Jun;26(6):723–730. doi: 10.1165/ajrcmb.26.6.4739. [DOI] [PubMed] [Google Scholar]
  37. Pierce J. A. Antitrypsin and emphysema. Perspective and prospects. JAMA. 1988 May 20;259(19):2890–2895. [PubMed] [Google Scholar]
  38. Piitulainen E., Eriksson S. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). Eur Respir J. 1999 Feb;13(2):247–251. doi: 10.1183/09031936.99.13224799. [DOI] [PubMed] [Google Scholar]
  39. Pittschieler K. Heterozygotes and liver involvement. Acta Paediatr Suppl. 1994 Feb;393:21–23. doi: 10.1111/j.1651-2227.1994.tb13202.x. [DOI] [PubMed] [Google Scholar]
  40. Sandford A. J., Weir T. D., Spinelli J. J., Paré P. D. Z and S mutations of the alpha1-antitrypsin gene and the risk of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 1999 Feb;20(2):287–291. doi: 10.1165/ajrcmb.20.2.3177. [DOI] [PubMed] [Google Scholar]
  41. Schievink W. I., Katzmann J. A., Piepgras D. G. Alpha-1-antitrypsin deficiency in spontaneous intracranial arterial dissections. Cerebrovasc Dis. 1998 Jan-Feb;8(1):42–44. doi: 10.1159/000015814. [DOI] [PubMed] [Google Scholar]
  42. Seersholm N., Kok-Jensen A., Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax. 1994 Jul;49(7):695–698. doi: 10.1136/thx.49.7.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Seixas S., Garcia O., Trovoada M. J., Santos M. T., Amorim A., Rocha J. Patterns of haplotype diversity within the serpin gene cluster at 14q32.1: insights into the natural history of the alpha1-antitrypsin polymorphism. Hum Genet. 2001 Jan;108(1):20–30. doi: 10.1007/s004390000434. [DOI] [PubMed] [Google Scholar]
  44. Sigsgaard T., Brandslund I., Omland O., Hjort C., Lund E. D., Pedersen O. F., Miller M. R. S and Z alpha1-antitrypsin alleles are risk factors for bronchial hyperresponsiveness in young farmers: an example of gene/environment interaction. Eur Respir J. 2000 Jul;16(1):50–55. doi: 10.1034/j.1399-3003.2000.16a09.x. [DOI] [PubMed] [Google Scholar]
  45. Tobin M. J., Cook P. J., Hutchison D. C. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest. 1983 Jan;77(1):14–27. doi: 10.1016/0007-0971(83)90002-5. [DOI] [PubMed] [Google Scholar]
  46. de Serres F. J., Blanco I., Fernández-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in southern Europe: France, Italy, Portugal and Spain. Clin Genet. 2003 Jun;63(6):490–509. doi: 10.1034/j.1399-0004.2003.00078.x. [DOI] [PubMed] [Google Scholar]
  47. de Serres Frederick J. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest. 2002 Nov;122(5):1818–1829. doi: 10.1378/chest.122.5.1818. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES